Paul Tudor Jones Tudor Investment Corp
Paul Tudor Jones is the founder of Tudor Investment Corporation and a pioneering macro trader. He rose to prominence after navigating the 1987 market crash successfully and has since built a multi-strategy firm spanning global markets. Jones is widely associated with discretionary macro trading, risk management discipline, and high-profile philanthropic efforts in education and the environment.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$459M |
| 2 |
Tesla
TSLA
|
+$216M |
| 3 |
WBS
Webster Financial
WBS
|
+$202M |
| 4 |
Warner Bros
WBD
|
+$198M |
| 5 |
Teck Resources
TECK
|
+$153M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core S&P 500 ETF
IVV
|
+$821M |
| 2 |
Invesco QQQ Trust
QQQ
|
+$220M |
| 3 |
NVIDIA
NVDA
|
+$211M |
| 4 |
EXAS
Exact Sciences
EXAS
|
+$201M |
| 5 |
CYBR
CyberArk
CYBR
|
+$159M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 70.89% |
| 2 | Technology | 5.79% |
| 3 | Financials | 4.4% |
| 4 | Consumer Discretionary | 3.69% |
| 5 | Industrials | 3.64% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2251
CALL
Frontline
FRO
$9.78B
| $1.15M | ﹤0.01% |
32,900
+16,900
| +106% | +$516K |
|
2252
Intellia Therapeutics
NTLA
$1.84B
| $1.14M | ﹤0.01% |
89,223
-99,853
| -53% | -$1.27M |
|
2253
CALL
Equinox Gold
EQX
$15.7B
| $1.14M | ﹤0.01% |
79,100
-42,300
| -35% | -$646K |
|
2254
Virtu Financial
VIRT
$5.91B
| $1.14M | ﹤0.01% |
25,874
-85,649
| -77% | -$3.34M |
|
|
KLAR
2255
PUT
Klarna Group
KLAR
$5.3B
| $1.14M | ﹤0.01% |
+86,900
| New | +$1.72M |
|
2256
PUT
Powell Industries
POWL
$7.01B
| $1.14M | ﹤0.01% |
6,300
+900
| +17% | +$147K |
|
|
CHCT
2257
Community Healthcare Trust
CHCT
$431M
| $1.14M | ﹤0.01% |
71,448
-75,079
| -51% | -$1.27M |
|
2258
PUT
Cenovus Energy
CVE
$58.5B
| $1.13M | ﹤0.01% |
+42,600
| New | +$908K |
|
2259
CALL
Advanced Energy
AEIS
$11.5B
| $1.13M | ﹤0.01% |
+3,500
| New | +$1.01M |
|
2260
Oppenheimer Holdings
OPY
$1.29B
| $1.13M | ﹤0.01% |
12,643
-15,105
| -54% | -$1.26M |
|
2261
Beam Therapeutics
BEAM
$3.15B
| $1.13M | ﹤0.01% |
47,310
+31,103
| +192% | +$863K |
|
2262
iShares National Muni Bond ETF
MUB
$45.5B
| $1.13M | ﹤0.01% |
+10,614
| New | +$1.14M |
|
2263
PUT
TPG
TPG
$9B
| $1.13M | ﹤0.01% |
+27,800
| New | +$1.43M |
|
2264
American Financial Group
AFG
$11.8B
| $1.12M | ﹤0.01% |
+8,804
| New | +$1.14M |
|
2265
Maravai LifeSciences
MRVI
$1.25B
| $1.12M | ﹤0.01% |
+396,915
| New | +$1.35M |
|
2266
Celldex Therapeutics
CLDX
$3.17B
| $1.12M | ﹤0.01% |
+35,393
| New | +$965K |
|
2267
PUT
Ovintiv
OVV
$18.1B
| $1.12M | ﹤0.01% |
+18,900
| New | +$912K |
|
2268
Ultragenyx Pharmaceutical
RARE
$2.59B
| $1.12M | ﹤0.01% |
53,517
+40,101
| +299% | +$903K |
|
2269
CALL
McEwen Inc
MUX
$1.33B
| $1.12M | ﹤0.01% |
54,900
-9,000
| -14% | -$214K |
|
2270
Gold Royalty Corp
GROY
$797M
| $1.12M | ﹤0.01% |
312,387
-574,305
| -65% | -$2.45M |
|
|
BNY
2271
PUT
Bank of New York Mellon
BNY
$110B
| $1.12M | ﹤0.01% |
9,400
+6,200
| +194% | +$737K |
|
2272
iShares 0-3 Month Treasury Bond ETF
SGOV
$104B
| $1.11M | ﹤0.01% |
+11,068
| New | +$1.11M |
|
2273
CALL
Deutsche Bank
DB
$75.3B
| $1.11M | ﹤0.01% |
37,400
-41,600
| -53% | -$1.47M |
|
|
GRMN
2274
CALL
Garmin
GRMN
$55.8B
| $1.11M | ﹤0.01% |
4,800
-2,800
| -37% | -$627K |
|
2275
CALL
CRISPR Therapeutics
CRSP
$5.74B
| $1.11M | ﹤0.01% |
23,400
-24,600
| -51% | -$1.3M |
|
Similar funds
Paul Tudor Jones's Q1 2026 Portfolio in Review
As of Q1 2026, Paul Tudor Jones held 4,438 positions worth $53.9B, down 0.3% from $54B the previous quarter. Its ten largest holdings account for 29% of the portfolio.
Paul Tudor Jones deployed $1.85B of net new capital in Q1 2026, opening 1,030 new positions and adding to 1,219 existing holdings. Its largest new stake was Warner Bros: 7,055,087 shares worth $194M.
By sector, the portfolio is most concentrated in Miscellaneous at 71% of assets, down from 73% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was iShares Core S&P 500 ETF, an estimated $821M trimmed.
- Paul Tudor Jones's largest Q1 2026 buy was Warner Bros: 7,055,087 shares worth $194M.
- Paul Tudor Jones added most to State Street SPDR S&P 500 ETF Trust in Q1 2026, an estimated $459M increase.
- Paul Tudor Jones's biggest Q1 2026 reduction was iShares Core S&P 500 ETF, cutting an estimated $821M.
- Paul Tudor Jones fully exited Exact Sciences in Q1 2026, selling an estimated $201M.
- Paul Tudor Jones's ten largest holdings make up 29% of its $53.9B portfolio in Q1 2026.
- Paul Tudor Jones opened 1,030 new positions and closed 924 in Q1 2026.
- Paul Tudor Jones's portfolio value fell 0.3% quarter-over-quarter to $53.9B.
Based on Tudor Investment Corp's 13F filing for Q1 2026, filed 15 May 2026.